Spago Nanomedical AB (OSTO:SPAGO) Marketable Securities: kr0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:SPAGO Spago Nanomedical AB OSTO:SPAGO
32 GF Score
Price kr0.10
GF Value kr0.03
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Spago Nanomedical AB Marketable Securities?

Spago Nanomedical AB OSTO:SPAGO -5.48% 32 Marketable Securities is kr0.00 Mil as of Jun. 2026. GuruFocus rates OSTO:SPAGO with a GF Score™ of 32/100 and a GF Value™ of kr0.03 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Spago Nanomedical AB's Marketable Securities for the quarter that ended in Jun. 2026 was kr0.00 Mil.

Spago Nanomedical AB  (OSTO:SPAGO) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Spago Nanomedical AB Marketable Securities Related Terms

Spago Nanomedical AB Marketable Securities Historical Data

* Premium members only.

The historical data trend for Spago Nanomedical AB's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spago Nanomedical AB Marketable Securities Chart

Spago Nanomedical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Spago Nanomedical AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:SPAGO
32GF Score
Spago Nanomedical AB OSTO:SPAGO
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spago Nanomedical AB Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of kr0.00 Mil mean?
Spago Nanomedical AB (OSTO:SPAGO) has a Marketable Securities of kr0.00 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Spago Nanomedical AB and its competitors.
Is Spago Nanomedical AB's Marketable Securities too high?
Spago Nanomedical AB's current Marketable Securities is kr0.00 Mil. Overall, Spago Nanomedical AB has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spago Nanomedical AB's Marketable Securities compare to VRTX and REGN?
Spago Nanomedical AB's Marketable Securities of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Spago Nanomedical AB and its competitors. Spago Nanomedical AB's current Marketable Securities is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spago Nanomedical AB stock overvalued right now?
Based on GuruFocus' analysis, Spago Nanomedical AB (OSTO:SPAGO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.03, compared to a current price of kr0.10 — trading 245% above its estimated fair value. The current Marketable Securities is kr0.00 Mil. Spago Nanomedical AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Spago Nanomedical AB (OSTO:SPAGO), the current Marketable Securities is kr0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spago Nanomedical AB (OSTO:SPAGO) Overvalued in 2026?

Based on GuruFocus' analysis, Spago Nanomedical AB stock appears to be overvalued. The current stock price of kr0.10 is trading 245% above its estimated GF Value™ of kr0.03. GuruFocus considers Spago Nanomedical AB to be Significantly Overvalued.

Key valuation signals for OSTO:SPAGO:

  • Marketable Securities: kr0.00 Mil
  • GF Value™: kr0.03 vs. price of kr0.10 (245% above fair value)
  • GF Score™: 32/100 with 4 warning signs

No single metric tells the full story. See the OSTO:SPAGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spago Nanomedical AB Business Description

Address Scheelevagen 22, Lund, SWE, SE-223 63
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.
32GF Score

Get the complete analysis for OSTO:SPAGO

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.10
Price
kr0.03
GF Value